Marmorino, F., Cremolini, C., Loupakis, F., Antoniotti, C., Barbara, C., Dargenio, F., . . . Falcone, A. (2016). PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study. Ann Oncol.
Dyfyniad Arddull ChicagoMarmorino, F., et al. "PD-004 Lactate Dehydrogenase (LDH) Levels Predict Benefit From the Continuation of Bevacizumab (bev) Beyond Progression in Metastatic Colorectal Cancer (mCRC): Subgroup Analysis of the Randomized BEBYP Study." Ann Oncol 2016.
Dyfyniad MLAMarmorino, F., et al. "PD-004 Lactate Dehydrogenase (LDH) Levels Predict Benefit From the Continuation of Bevacizumab (bev) Beyond Progression in Metastatic Colorectal Cancer (mCRC): Subgroup Analysis of the Randomized BEBYP Study." Ann Oncol 2016.